A Phase 1/2 study to determine the effect of EGFR targeted Doxorubicin loaded EnGeneIC Delivery Vehicles (VEDVDox) on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM) Expressing Epidermal Growth Factor Receptor (EGFR)
Latest Information Update: 08 Jun 2016
Price :
$35 *
At a glance
- Drugs Doxorubicin (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 24 Jun 2014 Status changed from recruiting to completed according to an EnGeneIC media release.
- 26 Mar 2013 New trial record